X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
oncology (51) 51
trastuzumab (51) 51
her2-targeted therapy (50) 50
index medicus (50) 50
breast cancer (48) 48
humans (46) 46
female (39) 39
breast neoplasms - drug therapy (29) 29
her2 (27) 27
receptor, erbb-2 - metabolism (25) 25
skin and connective tissue diseases (24) 24
cancer (23) 23
her2-targeted therapies (23) 23
breast neoplasms - pathology (21) 21
chemotherapy (18) 18
breast neoplasms - metabolism (16) 16
cell line, tumor (16) 16
pertuzumab (16) 16
animals (15) 15
epidermal growth factor (14) 14
receptor, erbb-2 - antagonists & inhibitors (14) 14
metastatic breast cancer (13) 13
resistance (13) 13
trastuzumab resistance (13) 13
antineoplastic agents - pharmacology (12) 12
antineoplastic agents - therapeutic use (12) 12
breast neoplasms - genetics (12) 12
care and treatment (12) 12
kinases (12) 12
lapatinib (12) 12
monoclonal-antibody (12) 12
survival (12) 12
erbb-2 protein (11) 11
neoplasms (11) 11
receptor, erbb-2 - genetics (11) 11
open-label (10) 10
cancer therapies (9) 9
medical prognosis (9) 9
metastasis (9) 9
mice (9) 9
pharmacology & pharmacy (9) 9
research (9) 9
therapy (9) 9
treatment outcome (9) 9
activation (8) 8
adjuvant chemotherapy (8) 8
aged (8) 8
analysis (8) 8
antibodies, monoclonal, humanized - pharmacology (8) 8
apoptosis (8) 8
drug resistance, neoplasm (8) 8
drug therapy (8) 8
growth (8) 8
health aspects (8) 8
medicine & public health (8) 8
middle aged (8) 8
molecular targeted therapy (8) 8
patients (8) 8
prognosis (8) 8
signal transduction (8) 8
trastuzumab - administration & dosage (8) 8
trastuzumab - therapeutic use (8) 8
tumors (8) 8
adult (7) 7
cardiotoxicity (7) 7
cell biology (7) 7
docetaxel (7) 7
growth-factor receptor (7) 7
medicine (7) 7
neoplasms. tumors. oncology. including cancer and carcinogens (7) 7
quinazolines - pharmacology (7) 7
signal transduction - drug effects (7) 7
acquired-resistance (6) 6
american society (6) 6
antitumor-activity (6) 6
breast neoplasms - mortality (6) 6
breast-cancer (6) 6
cancer cells (6) 6
cell proliferation - drug effects (6) 6
double-blind (6) 6
drug resistance, neoplasm - genetics (6) 6
genetic aspects (6) 6
her2-positive (6) 6
her2-positive breast cancer (6) 6
human epidermal growth factor receptor 2 (6) 6
inhibition (6) 6
mechanisms (6) 6
medical research (6) 6
metastatic breast-cancer (6) 6
original research (6) 6
phosphorylation (6) 6
protein kinase inhibitors - pharmacology (6) 6
xenograft model antitumor assays (6) 6
adjuvant trastuzumab (5) 5
anthracyclines (5) 5
antibodies, monoclonal, humanized - administration & dosage (5) 5
antineoplastic combined chemotherapy protocols - therapeutic use (5) 5
apoptosis - drug effects (5) 5
cells (5) 5
clinical trials (5) 5
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Breast Cancer, ISSN 1340-6868, 3/2015, Volume 22, Issue 2, pp. 101 - 116
Over the past decade, the management of HER2-positive breast cancer has evolved dramatically. In addition to advances in screening, genetic testing, imaging,... 
HER2-targeted therapy | Oncology | Adjuvant therapy | Neoadjuvant treatment | Medicine & Public Health | Pertuzumab | Surgery | Cancer Research | Lapatinib | Ado-trastuzumab emtansine | Bresat cancer | HER2-directed therapy | Surgical Oncology | Trastuzumab | 1ST-LINE TREATMENT | OPEN-LABEL | MONOCLONAL-ANTIBODY | TRASTUZUMAB RESISTANCE | ADJUVANT TRASTUZUMAB | OBSTETRICS & GYNECOLOGY | PREOPERATIVE CHEMOTHERAPY | ONCOLOGY | RANDOMIZED PHASE-II | TYROSINE KINASE INHIBITOR | LAPATINIB PLUS CAPECITABINE | NEOADJUVANT PERTUZUMAB | Breast Neoplasms - surgery | Small Molecule Libraries - pharmacology | Humans | Receptor, ErbB-2 - metabolism | Antibodies, Monoclonal - therapeutic use | Antineoplastic Agents - therapeutic use | Molecular Targeted Therapy | Maytansine - pharmacology | Breast Neoplasms - metabolism | Antibodies, Monoclonal, Humanized - pharmacology | Female | Neoadjuvant Therapy | Quinazolines - administration & dosage | Antineoplastic Agents - pharmacology | Receptor, ErbB-2 - antagonists & inhibitors | Trastuzumab - pharmacology | Antibodies, Monoclonal, Humanized - therapeutic use | Trastuzumab - therapeutic use | Maytansine - analogs & derivatives | Trastuzumab - administration & dosage | Maytansine - therapeutic use | Breast Neoplasms - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Quinazolines - therapeutic use | Drug Resistance, Neoplasm - drug effects | Care and treatment | Chemotherapy | Breast cancer | Biological products | Cancer
Journal Article
Journal Article
Journal Article
Breast cancer research : BCR, ISSN 1465-542X, 11/2018, Volume 20, Issue 1, pp. 140 - 18
BackgroundJunctional adhesion molecule-A (JAM-A) is an adhesion molecule whose overexpression on breast tumor tissue has been associated with aggressive cancer... 
Herceptin | HER2-targeted therapies | Tight junction | Breast cancer | JAM-A | Lapatinib | Drug resistance | HER2 | Trastuzumab | KINASE INHIBITOR | TRASTUZUMAB RESISTANCE | CHEMOTHERAPY | ONCOLOGY | RECOMMENDATIONS | POOR-PROGNOSIS | GROWTH | EXPRESSION | IMMUNOHISTOCHEMISTRY
Journal Article
Breast Cancer Research and Treatment, ISSN 0167-6806, 1/2015, Volume 149, Issue 2, pp. 373 - 383
The PI3K pathway is a key mechanism of trastuzumab resistance, but early attempts to indirectly target this pathway with mTOR inhibitors have had limited... 
HER2-positive breast cancer | Medicine & Public Health | PI3K inhibitor | Reverse phase protein array | Oncology | Acquired resistance to HER2-targeted therapies | Sequenom MassArray | SURVIVAL | PIK3CA MUTATIONS | METASTASIS | KINASE | CELL LINES | AKT | ONCOLOGY | PATHWAY | HER2 | UP-REGULATION | EXPRESSION | Receptor, ErbB-2 - genetics | TOR Serine-Threonine Kinases - metabolism | Humans | Receptor, ErbB-2 - metabolism | Drug Resistance, Neoplasm | Phosphatidylinositol 3-Kinases - metabolism | Antineoplastic Agents - administration & dosage | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Breast Neoplasms - metabolism | Antibodies, Monoclonal, Humanized - administration & dosage | Antibodies, Monoclonal, Humanized - pharmacology | Inhibitory Concentration 50 | Female | Quinazolines - administration & dosage | Antineoplastic Agents - pharmacology | Receptor, ErbB-2 - antagonists & inhibitors | Drug Evaluation, Preclinical | Pyrimidines - administration & dosage | PTEN Phosphohydrolase - metabolism | Pyrimidines - pharmacology | Breast Neoplasms - drug therapy | Drug Synergism | Phosphatidylinositol 3-Kinases - genetics | Protein Kinase Inhibitors - administration & dosage | Breast Neoplasms - genetics | MAP Kinase Signaling System - drug effects | Signal Transduction - drug effects | Protein Kinase Inhibitors - pharmacology | Mutation | Quinazolines - pharmacology | Trastuzumab | Tumor proteins | Analysis | Breast cancer
Journal Article
Expert Review of Clinical Pharmacology, ISSN 1751-2433, 01/2019, Volume 12, Issue 1, pp. 9 - 16
Introduction: Patients with early HER2-positive breast cancer (BC) benefit from HER2-targeted systemic therapy. The endorsed standard adjuvant treatment for... 
HER2-targeted therapy | breast cancer | HER2-positive breast cancer | Adjuvant trastuzumab duration | FINAL ANALYSIS | TRASTUZUMAB | PHASE-II | FOLLOW-UP | OPEN-LABEL | HER2-POSITIVE BREAST-CANCER | CHEMOTHERAPY REGIMENS | 5-YEAR ANALYSIS | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | NEOADJUVANT
Journal Article
Journal Article
Breast Cancer Research and Treatment, ISSN 0167-6806, 9/2018, Volume 171, Issue 2, pp. 371 - 381
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 05/2010, Volume 16, Issue 9, pp. 2688 - 2695
Journal Article